On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) had awarded a two-year Small Business Innovation Research (SBIR) contract to fund the development of the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines.

This project build on the inventions of co-collaborators Dr. Sara Lustigman of New York Blood Center and Dr. Florian Krammer of the Icahn School of Medicine, Mount Sinai in New York.

Celdara Medical is an experienced biopharma developer focused on launching promising products to the patients who need them the most.